This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kato, J. Articles by Niitsu, Y. Search for Related Content PubMed PubMed Citation Articles by Kato, J. Articles by Niitsu, Y.

Normalization of Elevated Hepatic 8-Hydroxy-2'-Deoxyguanosine Levels in Chronic Hepatitis C Patients by Phlebotomy and Low Iron Diet¹

Fourth Department of Internal Medicine [J. K., T. N., G. K., K. T., R. T., Y. S., K. F., M. T., T. T., Y. N.] and Department of Molecular Medicine [M. K.], Sapporo Medical University School of Medicine, and Department of Clinical Pathology, Sapporo Medical University Hospital [T. I.], Sapporo 060-8543, Japan

Accumulation of 8-hydroxy-2'-deoxyguanosine (8-OHdG) in DNA, which may result from the continuous reactive oxygen species (ROS) generation associated with chronic inflammation, has been reported in various human preneoplastic lesions and in cancerous tissues. However, no direct causative relationship between the 8-OHdG formation and carcinogenesis has been thus far demonstrated in humans. Directly proving the causality requires showing that depletion of 8-OHdG levels in tissue by interfering with ROS generation results in a reduction in cancer. Chronic hepatitis C virus (HCV) infection is associated with a high risk of hepatocellular carcinoma (HCC). Several studies on patients with chronic HCV have shown that hepatic iron overload is attributable to liver injury and that iron depletion improved serum aminotransferase levels. Excess iron is known to generate ROS within cells, which causes mutagenic lesions, such as 8-OHdG. In this study, therefore, we have evaluated whether therapeutic iron reduction (phlebotomy and low iron diet) with a long-term follow-up (6 years) would decrease the hepatic 8-OHdG levels and the risk of HCC development in patients with chronic HCV. Patients (34) enrolled were those who had undergone standard IFN therapy but had no sustained response. Quantitative immunohistochemistry using the KS-400 image analyzing system and electrochemical detection was used for 8-OHdG detection. With this treatment, elevated hepatic 8-OHdG levels in patients with chronic hepatitis C (8.3 ± 4.6/10⁵ dG) significantly decreased to almost normal levels (2.2 ± 0.9/10⁵ dG; P < 0.001) with concomitant improvement of hepatitis severity, including fibrosis, whereas HCV titers were unaffected. None of these patients developed HCC. Thus, long-term iron reduction therapy in patients with chronic hepatitis C may potentially lower the risk of progression to HCC.

This article has been cited by other articles:

				K.-L. Kuo, S.-C. Hung, Y.-H. Wei, and D.-C. Tarng Intravenous Iron Exacerbates Oxidative DNA Damage in Peripheral Blood Lymphocytes in Chronic Hemodialysis Patients J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1817 - 1826. [Abstract] [Full Text] [PDF]

				K. Otogawa, T. Ogawa, R. Shiga, K. Nakatani, K. Ikeda, Y. Nakajima, and N. Kawada Attenuation of acute and chronic liver injury in rats by iron-deficient diet Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R311 - R320. [Abstract] [Full Text] [PDF]

				K. Yamaguchi, M. Mandai, S. Toyokuni, J. Hamanishi, T. Higuchi, K. Takakura, and S. Fujii Contents of Endometriotic Cysts, Especially the High Concentration of Free Iron, Are a Possible Cause of Carcinogenesis in the Cysts through the Iron-Induced Persistent Oxidative Stress Clin. Cancer Res., January 1, 2008; 14(1): 32 - 40. [Abstract] [Full Text] [PDF]

				C.-C. Tsai, S.-C. Kao, C.-Y. Cheng, H.-C. Kau, W.-M. Hsu, C.-F. Lee, and Y.-H. Wei Oxidative Stress Change by Systemic Corticosteroid Treatment Among Patients Having Active Graves Ophthalmopathy Arch Ophthalmol, December 1, 2007; 125(12): 1652 - 1656. [Abstract] [Full Text] [PDF]

				R. J. Epstein and T. W. Leung Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies Clin. Cancer Res., January 1, 2007; 13(1): 11 - 17. [Abstract] [Full Text] [PDF]

				K. Machida, K. T.-H. Cheng, C.-K. Lai, K.-S. Jeng, V. M.-H. Sung, and M. M. C. Lai Hepatitis C Virus Triggers Mitochondrial Permeability Transition with Production of Reactive Oxygen Species, Leading to DNA Damage and STAT3 Activation J. Virol., July 15, 2006; 80(14): 7199 - 7207. [Abstract] [Full Text] [PDF]

				A M Emara, R S El Kelany, and K A Moustafa Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats Human and Experimental Toxicology, July 1, 2006; 25(7): 375 - 385. [Abstract] [PDF]

				T. Katahira, T. Takayama, K. Miyanishi, T. Hayashi, T. Ikeda, Y. Takahashi, R. Takimoto, T. Matsunaga, J. Kato, and Y. Niitsu Plasma Glutathione S-Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin's Lymphoma (Stages III and IV) Clin. Cancer Res., December 1, 2004; 10(23): 7934 - 7940. [Abstract] [Full Text] [PDF]

				K. Hino and K. Okita Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C J. Antimicrob. Chemother., January 1, 2004; 53(1): 19 - 22. [Abstract] [Full Text] [PDF]

				H. Hisai, J. Kato, M. Kobune, T. Murakami, K. Miyanishi, M. Takahashi, N. Yoshizaki, R. Takimoto, T. Terui, and Y. Niitsu Increased Expression of Angiogenin in Hepatocellular Carcinoma in Correlation with Tumor Vascularity Clin. Cancer Res., October 15, 2003; 9(13): 4852 - 4859. [Abstract] [Full Text] [PDF]

				M. S. COOKE, M. D. EVANS, M. DIZDAROGLU, and J. LUNEC Oxidative DNA damage: mechanisms, mutation, and disease FASEB J, July 1, 2003; 17(10): 1195 - 1214. [Abstract] [Full Text] [PDF]